Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canagliflozin/metformin extended-release - Assertio Therapeutics /Janssen

Next Previous
Search
Drug Profile

Canagliflozin/metformin extended-release - Assertio Therapeutics /Janssen

Alternative Names: CANA/MET XR FDC; Invokamet XR; Metformin extended-release/canagliflozin - Assertio Therapeutics/Janssen

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Depomed; Janssen Pharmaceutica
  • Developer Assertio Therapeutics; Janssen Pharmaceutica
  • Class Antihyperglycaemics; Biguanides; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Aug 2018 Depomed is now called Assertio Therapeutics
  • 03 Aug 2018 Chemical structure information added
  • 13 Jul 2018 US FDA assigns PDUFA action date of 31/10/2018 for canagliflozin for the sNDA to reduce the risk of major adverse cardiovascular events in Type-2 diabetes mellitus

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top